|
|
 |
|
Viewing report
|
|
 |
 |
Central Nervous System - Dementia Drug Pipeline Report
Life Science Analytics, June 2007, Pages: 11
Life Science Analytics, 'Central Nervous System - Dementia Drug Pipeline Report' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of dementia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas. - Keep track of your competitors and partners by better understanding their product pipeline. - Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas. - Maintain a critical competitive advantage.
Customers who bought this item also bought
Central Nervous System Dementia
New Drug Futures: Central Nervous System Chapter
Stakeholder Perspectives: Mild Cognitive Impairment and Dementia - Aricept in race to pioneer unexplored markets
AIIRBS: Benefits Beyond Blood Pressure: Seeking Indications Throughout The Cardiovascular Continuum
Japanese Patient Population Analysis and Epidemiological Survey 2007 Volume 2
Inhaled CNS Therapeutics - Markets & Opportunities
Pathology at a Glance
Special Report: Key Pricing and Reimbursement Trends for CNS Drugs
Neuroprotection - Drugs, Markets and Companies
Oxford Comprehensive Textbook of AIDS Psychiatry
The Top 50 Contract Research Organisations In Europe For CNS Diseases & Disorders
Stakeholder Opinions: Parkinsons Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market
|
 |
|
|